Systemic delivery of a novel liver-detargeted oncolytic adenovirus causes reduced liver toxicity but maintains the antitumor response in a breast cancer bone metastasis model

Human Gene Therapy

Volumn 22, Issue 9, 2011, Pages 1137-1142

  Zhang, Zhenwei ^a   Krimmel, Jeffrey ^a   Zhang, Zhiling ^a   Hu, Zebin ^a   Seth, Prem ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10; LIVER ENZYME; ONCOLYTIC ADENOVIRUS; ONCOLYTIC ADENOVIRUS MHAD LUC2; ONCOLYTIC ADENOVIRUS TYPE 5; ONCOLYTIC VIRUS AD LUC2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; BONE TUMOR; BREAST CANCER; BREAST TUMOR; CANCER CELL; CONTROLLED STUDY; DEATH; DISEASE MODEL; DRUG BINDING; DRUG MEGADOSE; DRUG UPTAKE; FEMALE; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER INJURY; LOW DRUG DOSE; MOUSE; NONHUMAN; SEROTYPE; SINGLE DRUG DOSE; TOXICITY; TUMOR CELL;

ADENOVIRIDAE; ANIMALS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENETIC VECTORS; HEK293 CELLS; HUMANS; LIVER; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; TRANSDUCTION, GENETIC; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; ANIMALIA; HUMAN ADENOVIRUS TYPE 5; MUS; MUS MUSCULUS;

EID: 80052996914     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2011.003     Document Type: Article

References (24)

1. Alba, R., Bradshaw, A.C., Parker, A.L., et al. (2009). Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: Effect of mutagenesis on FX interactions and gene transfer. Blood 114, 965-971.
2. American Cancer Society. (2010). Cancer Facts and Figures 2010 (American Cancer Society).
3. Bischoff, J.R., Kirn, D.H., Williams, A., et al. (1996). An adeno-virus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373-376. (Pubitemid 26353341)
4. Coleman, R.E. (2001). Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev. 27, 165-176. (Pubitemid 32452017)
5. Crompton, A.M., and Kirn, D.H. (2007). From ONYX-015 to armed vaccinia viruses: The education and evolution of onco-lytic virus development. Curr. Cancer Drug Targets 7, 133-139. (Pubitemid 46348627)
6. de Vrij, J., Willemsen, R.A., Lindholm, L., et al. (2010). Adeno-virus-derived vectors for prostate cancer gene therapy. Hum. Gene Ther. 21, 795-805.
7. Howe, J.A., Demers, G.W., Johnson, D.E., et al. (2000). Evaluation of E1-mutant adenoviruses as conditionally replicating agents for cancer therapy. Mol. Ther. 2, 485-495.
8. Hu, Z., Robbins, J.S., Pister, A., et al. (2010a). A modified hTERT promoter-directed oncolytic adenovirus replication with concurrent inhibition of TGFb signaling for breast cancer therapy. Cancer Gene Ther. 17, 235-243.
9. Hu, Z., Zhang, Z., Guise, T., and Seth, P. (2010b). Systemic delivery of an oncolytic adenovirus expressing soluble transforming growth factor-b receptor II-Fc fusion protein can inhibit breast cancer bone metastasis in a mouse model. Hum. Gene Ther. 21, 1623-1629.
10. Kalyuzhniy, O., Di Paolo, N.C., Silvestry, M., et al. (2008). Ade-novirus serotype 5 hexon is critical for virus infection of he-patocytes in vivo. Proc. Natl. Acad. Sci. U.S.A. 105, 5483-5488. (Pubitemid 351753889)
11. Katayose, D., Gudas, J., Nguyen, H., et al. (1995). Cytotoxic effects of adenovirus-mediated wild-type p53 protein expression in normal and tumor mammary epithelial cells. Clin. Cancer Res. 1, 889-897.
12. McCormick, F. (2005). Future prospects for oncolytic therapy. Oncogene 24, 7817-7819. (Pubitemid 41670682)
13. National Institutes of Health. ImageJ. (U.S. National Institutes of Health, Bethesda, MD). Available at http://rsb.info.nih.gov/ij/
14. Parker, A.L., Waddington, S.N., Nicol, C.G., et al. (2006). Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood 108, 2554-2561.
15. Prill, J.M., Espenlaub, S., Samen, U., et al. (2011). Modifications of adenovirus hexon allow for either hepatocyte detargeting or targeting with potential evasion from Kupffer cells. Mol. Ther. 19, 83-92.
16. Roberts, D.M., Nanda, A., Havenga, M.J., et al. (2006). Hexon-chimaeric adenovirus serotype 5 vectors circumvent preexisting anti-vector immunity. Nature 441, 239-243.
17. Seth, P., ed. (1999). Adenoviruses: Basic Biology to Gene Therapy (R.G. Landes, Austin, TX).
18. Seth, P., Wang, Z.G., Pister, A., et al. (2006). Development of oncolytic adenovirus armed with a fusion of soluble transforming growth factor-b receptor II and human immuno-globulin Fc for breast cancer therapy. Hum. Gene Ther. 17, 1152-1160. (Pubitemid 44749716)
19. Shashkova, E.V., Doronin, K., Senac, J.S., and Barry, M.A. (2008). Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with on-colytic adenovirus. Cancer Res. 68, 5896-5904.
20. Short, J.J., Rivera, A.A., Wu, H., et al. (2010). Substitution of adenovirus serotype 3 hexon onto a serotype 5 oncolytic ad-enovirus reduces factor X binding, decreases liver tropism, and improves antitumor efficacy. Mol. Cancer Ther. 9, 2536-2544.
21. Waddington, S.N., McVey, J.H., Bhella, D., et al. (2008). Adeno-virus serotype 5 hexon mediates liver gene transfer. Cell 132, 397-409. (Pubitemid 351200513)
22. Xu, Z., Tian, J., Smith, J.S., and Byrnes, A.P. (2008). Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement. J. Virol. 82, 11705-11713.
23. Yamamoto, M., and Curiel, D.T. (2010). Current issues and future directions of oncolytic adenoviruses. Mol. Ther. 18, 243-250.
24. Yin, J.J., Selander, K., Chirgwin, J.M., et al. (1999). TGF-b signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 103, 197-206. (Pubitemid 29053137)